Making sense of the Global Market, Euromonitor International Ltd.

Yu Mitsuhashi

Making sense of the Global Market

Euromonitor International Ltd.

We are a global market research company focused on industries, countries, economies and consumers worldwide. Our cross-country comparable research helps your organisation identify opportunities and develop growth strategies in countries and regions across the globe. With offices around the world, 1,200 analysts in 100 countries and market research on every key trend and driver, we give you powerful access to the real story behind consumer change.

Thematic (Sector/Industry)

<ul><li>Baby food records retail value growth and retail volume growth of 5% in 2017, reaching VND32.3 trillion and 108,000 tonnes</li><li>The price ceiling for milk formula is officially lifted on 1 April 2017</li><li>Liquid growing-up milk formula posts the strongest value growth of 2017, with a 15% sales increase</li><li>The average unit price of baby food increases in 2017</li><li>Vietnam Dairy Products JSC (Vinamilk) remains the leader in 2017, with a value share of 28%</li><li>Baby food is expected to record a value CAGR of 2% at constant 2017 prices over the forecast period, and reach VND36.3 trillion in 2022</li></ul>

Baby food records retail value growth and retail volume growth of 5% in 2017, reaching VND32.3 trillion and 108,000 tonnesThe price ceiling for milk formula is officially lifted on 1 April 2017Liquid growing-up milk formula posts the strongest value growth of 2017, with a 15% sales increaseThe average unit price of baby food increases in 2017Vietnam Dairy Products JSC (Vinamilk) remains the leader in 2017, with a value share of 28%Baby food is expected to record a value CAGR of 2% at constant 2017 prices over the forecast period, and reach VND36.3 trillion in 2022

<ul class=""><li>Baby food sees 16% retail value growth in 2017 to reach INR47.0 billion</li><li>Baby food benefits from the role of medical representatives promoting their products through doctors</li><li>Milk formula achieves growth of 16% during 2017 in retail value terms to reach INR25.2 billion</li><li>Average unit price increases by 10% in 2017</li><li>Nestlé India Ltd remains dominant with a value share of 63% in 2017</li><li>Baby food is expected to see an 8% constant 2017 value CAGR over the forecast period to reach INR69.8 billion in 2022</li></ul>

Baby food sees 16% retail value growth in 2017 to reach INR47.0 billionBaby food benefits from the role of medical representatives promoting their products through doctorsMilk formula achieves growth of 16% during 2017 in retail value terms to reach INR25.2 billionAverage unit price increases by 10% in 2017Nestlé India Ltd remains dominant with a value share of 63% in 2017Baby food is expected to see an 8% constant 2017 value CAGR over the forecast period to reach INR69.8 billion in 2022

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

Eris Lifesciences / Equity Capital Markets

Eris Lifesciences plans to raise US$270m in its IPO through a selldown of shares by a ChrysCapital, a PE investor, and the founders. Our fellow Insight Provider, <a href="https://www.smartkarma.com/profiles/13" target="_blank" data-smartkarma-citation="accounts:13">Kemp Dolliver, CFA</a>, covered part of the deal in his earlier insight, <a href="https://www.smartkarma.com/insights/eris-lifesciences-ask-some-questions-take-the-deal" target="_blank" data-smartkarma-citation="insights:11423">Eris Lifesciences: Ask Some Questions, Take the Deal</a>.In this insight, we will run the deal through our framework, discuss  more about the company and analyse its bottomline growth which has primarily been driven by margin expansion, and we also discuss valuations.

Eris Lifesciences plans to raise US$270m in its IPO through a selldown of shares by a ChrysCapital, a PE investor, and the founders. Our fellow Insight Provider, Kemp Dolliver, CFA, covered part of the deal in his earlier insight, Eris Lifesciences: Ask Some Questions, Take the Deal.In this insight, we will run the deal through our framework, discuss  more about the company and analyse its bottomline growth which has primarily been driven by margin expansion, and we also discuss valuations.

Eris Lifesciences IPO - Rich Valuations at What Appears to Be Unsustainably High Margins

Asia focused research insights & advisory, Asia Advisors

Vinay Patel

Asia focused research insights & advisory

Asia Advisors

Asia Advisors is an independent financial advisory and research firm working closely with corporates and institutions to provide consulting solutions & research insights. We provide advisory services including capital solutions, business strategy and investment insights.
Firm is headed by Vinay Patel who has close to two decades of experience in research and business development at large, international investment banks such as HSBC and ICICI Securities. Led research efforts in areas of Macroeconomics, Asset Allocation & Investment Strategy for close to a decade in global & domestic research teams. As a business head in Singapore, advised top global investment management firms & Portfolio managers in Asia for India related investments.
Vinay was recently joined by Swapnil Manish, an investment banker and ex-ecommerce entrepreneur with more than 12 years of experience. Swapnil was the TMT banker at BNP Paribas and was part of several large M&A and ECM transactions (Bharti-Zain, Bharti Infratel IPO, Schneider-Zicom among several others). He's also had a stint as an ecommerce entrepreneur having launched & led Mumbai's first online grocery player.

Primary issuances are expected to remain strong in 2017 following a five-year high in funds raised in 2016 (Rs 220bn) even as Fed rate expectations weigh on the broader secondary market outlook for India. Data shows that primary issuances in previous years have bucked the trend of weak capital inflows and in our view companies evaluate sector appetite &amp; valuations levels before deciding on a public issue. For e.g. in the recent past, CY2015 hardly recorded any significant FII inflows however the…

Primary issuances are expected to remain strong in 2017 following a five-year high in funds raised in 2016 (Rs 220bn) even as Fed rate expectations weigh on the broader secondary market outlook for India. Data shows that primary issuances in previous years have bucked the trend of weak capital inflows and in our view companies evaluate sector appetite &amp; valuations levels before deciding on a public issue. For e.g. in the recent past, CY2015 hardly recorded any significant FII inflows however the…

IPO Pipeline to Remain Strong as PE Funds, Quasi-Govt Promoters Aim for Portfolio Exits

Frontier and emerging markets (Vietnam)

Dylan Waller

Nomadic Equity

Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's healthcare industry. Medisetter is an international online medical travel search and bookings platform offering a one-stop-shop medical travel booking and planning service. Prospective patients can search and compare hospitals and clinics across different countries, receive price quotes, book appointments and also book accommodation, translators and…

Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's healthcare industry. Medisetter is an international online medical travel search and bookings platform offering a one-stop-shop medical travel booking and planning service. Prospective patients can search and compare hospitals and clinics across different countries, receive price quotes, book appointments and also book accommodation, translators and…

MediSetter Interview: Insight on Opportunities in Asia's Healthcare Industry

India

Abbott India Limited manufactures a wide range of pharmaceutical and medical products, agrochemicals, and animal health products. The Company's medical and pharmaceutical products include insulin injections, anti-dysentery drugs, vitamin preparations, penicillin preparations, sulfonamide tablets, and a variety of household remedies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Abbott India (BOOT IN)

Sector Capsule: Baby Food in Vietnam

Baby food records retail value growth and retail volume growth of 5% in 2017, reaching VND32.3 trillion and 108,000 tonnes The price ceiling for...

Euromonitor International Ltd.

Sector Capsule: Baby Food in India

Baby food sees 16% retail value growth in 2017 to reach INR47.0 billion Baby food benefits from the role of medical representatives promoting...

Euromonitor International Ltd.

Eris Lifesciences IPO - Rich Valuations at What Appears to Be Unsustainably High Margins

Eris Lifesciences plans to raise US$270m in its IPO through a selldown of shares by a ChrysCapital, a PE investor, and the founders. Our fellow...

Sumeet Singh

IPO Pipeline to Remain Strong as PE Funds, Quasi-Govt Promoters Aim for Portfolio Exits

Primary issuances are expected to remain strong in 2017 following a five-year high in funds raised in 2016 (Rs 220bn) even as Fed rate expectations...

Asia Advisors

MediSetter Interview: Insight on Opportunities in Asia's Healthcare Industry

Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's...

Nomadic Equity

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)